Parallax Volatility Advisers, L.P. Amicus Therapeutics, Inc. Transaction History

Parallax Volatility Advisers, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$13.47 - $24.89 $211,802 - $391,370	-15,724 Reduced 84.07%	2,980 $69,000
Q3 2020 Nov 13, 2020	SELL	$12.89 - $15.89 $339,625 - $418,669	-26,348 Reduced 58.48%	18,704 $264,000
Q2 2019 Aug 14, 2019	BUY	$10.96 - $14.4 $493,769 - $648,748	45,052 New	45,052 $562,000
Q1 2019 May 15, 2019	SELL	$10.04 - $13.92 $863 - $1,197	-86 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$8.38 - $13.44 $312,808 - $501,688	-37,328 Reduced 99.77%	86 $1,000
Q3 2018 Nov 14, 2018	SELL	$11.6 - $16.54 $577,807 - $823,873	-49,811 Reduced 57.11%	37,414 $452,000
Q2 2018 Aug 14, 2018	BUY	$13.13 - $17.09 $979,498 - $1.27 Million	74,600 Added 590.89%	87,225 $1.36 Million
Q1 2018 May 15, 2018	SELL	$13.76 - $17.12 $1.06 Million - $1.32 Million	-77,048 Reduced 85.92%	12,625 $190,000
Q4 2017 Feb 14, 2018	SELL	$12.51 - $16.24 $538,555 - $699,131	-43,050 Reduced 32.44%	89,673 $1.29 Million
Q3 2017 Nov 14, 2017	BUY	$11.74 - $15.78 $1.56 Million - $2.09 Million	132,723	132,723 $2 Million

311

312M

516K

833K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.69B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.